Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Non-Current Assets (2021 - 2025)

Senti Biosciences has reported Non-Current Assets over the past 5 years, most recently at $27.9 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $27.9 million for Q4 2025, down 28.11% from a year ago — trailing twelve months through Dec 2025 was $136.1 million (down 19.16% YoY), and the annual figure for FY2025 was $27.9 million, down 28.11%.
  • Non-Current Assets for Q4 2025 was $27.9 million at Senti Biosciences, down from $34.5 million in the prior quarter.
  • Over the last five years, Non-Current Assets for SNTI hit a ceiling of $230.1 million in Q1 2022 and a floor of $27.9 million in Q4 2025.
  • Median Non-Current Assets over the past 5 years was $48.3 million (2023), compared with a mean of $78.9 million.
  • Peak annual rise in Non-Current Assets hit 114.23% in 2022, while the deepest fall reached 74.59% in 2022.
  • Senti Biosciences' Non-Current Assets stood at $36.5 million in 2021, then surged by 114.23% to $78.2 million in 2022, then plummeted by 38.27% to $48.3 million in 2023, then decreased by 19.48% to $38.9 million in 2024, then fell by 28.11% to $27.9 million in 2025.
  • The last three reported values for Non-Current Assets were $27.9 million (Q4 2025), $34.5 million (Q3 2025), and $36.0 million (Q2 2025) per Business Quant data.